Fulcrum Asset Management LLP Purchases 72,692 Shares of Sarepta Therapeutics, Inc. $SRPT

Fulcrum Asset Management LLP lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14,895.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,180 shares of the biotechnology company’s stock after buying an additional 72,692 shares during the period. Fulcrum Asset Management LLP’s holdings in Sarepta Therapeutics were worth $1,364,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at approximately $27,000. Pinnacle Wealth Planning Services Inc. boosted its position in Sarepta Therapeutics by 50.6% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 598 shares during the last quarter. Nykredit A S bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $43,000. Ancora Advisors LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $45,000. Finally, Allworth Financial LP bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $58,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on SRPT shares. William Blair upgraded shares of Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Deutsche Bank upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating and increased their target price for the stock from $14.00 to $18.00 in a report on Tuesday. JPMorgan Chase & Co. decreased their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. HC Wainwright reiterated a “sell” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 5th. Finally, Benchmark reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $23.67.

Sarepta Therapeutics Stock Up 1.6%

SRPT stock opened at $16.68 on Thursday. The company has a quick ratio of 2.13, a current ratio of 3.46 and a debt-to-equity ratio of 0.46. The business has a 50 day moving average price of $18.87 and a two-hundred day moving average price of $18.57. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -12.18, a P/E/G ratio of 0.39 and a beta of 0.45. Sarepta Therapeutics, Inc. has a twelve month low of $14.68 and a twelve month high of $24.68.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $381.35 million for the quarter, compared to analysts’ expectations of $352.20 million. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The business’s revenue was down 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.13) EPS. Analysts anticipate that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.